Department of Neurology, Danish Headache Center, University of Copenhagen, Glostrup Hospital, Glostrup, Denmark.
J Headache Pain. 2011 Jun;12(3):275-80. doi: 10.1007/s10194-011-0309-5. Epub 2011 Feb 25.
Dose-response curves for headaches relief and adverse events (AEs) are presented for five triptans: sumatriptan, zolmitriptan, naratriptan, almotriptan, and frovatriptan, and the CGRP antagonist telcagepant. The upper part of the efficacy curve of the triptans is generally flat, the so-called ceiling effect; and none of the oral triptans, even in high doses, are as effective as subcutaneous sumatriptan, In contrast, AEs increases with increasing dose without a ceiling effect. The optimal dose for the triptans is mainly determined by tolerability. Telcagepant has an excellent tolerability and can be used in migraine patients with cardiovascular co-morbidity. Based on the literature the triptans and telcagepant are rated in a table for efficacy and tolerability.
头痛缓解和不良反应(AE)的剂量反应曲线展示了五种曲坦类药物:舒马曲坦、佐米曲坦、那拉曲坦、阿莫曲坦和夫罗曲坦,以及 CGRP 拮抗剂 telcagepant。曲坦类药物的疗效曲线的上半部分通常是平坦的,即所谓的“天花板效应”;而且,即使是高剂量的口服曲坦类药物,也不如皮下注射的舒马曲坦有效。相比之下,AE 随着剂量的增加而增加,没有天花板效应。曲坦类药物的最佳剂量主要取决于耐受性。telcagepant 具有极好的耐受性,可用于伴有心血管合并症的偏头痛患者。根据文献,曲坦类药物和 telcagepant 在疗效和耐受性方面进行了评级。